John J Rinehart
Overview
Explore the profile of John J Rinehart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howard M, Lu X, Rinehart J, Jay M, Dziubla T
Langmuir
. 2012 Jul;
28(33):12030-7.
PMID: 22830432
Despite the importance of PEGylation in achieving long nanoparticle circulation times, many nanoparticles are coated with PEGylating agents susceptible to enzymatic degradation. In this study, solid lipid nanoparticles (SLNs) prepared...
2.
Howard M, Lu X, Rinehart J, Jay M, Dziubla T
Langmuir
. 2010 Dec;
27(5):1964-71.
PMID: 21190351
As the physicochemical characteristics of solid lipid nanoparticles (SLNs) play a critical role in their success, it is important to understand how the materials and process used in their preparation...
3.
Kim J, Howard M, Dziubla T, Rinehart J, Jay M, Lu X
ACS Nano
. 2010 Dec;
5(1):209-16.
PMID: 21158414
Nanocarrier systems are frequently characterized by their size distribution, while drug encapsulation in nanocarriers is generally characterized in terms of an entire population, assuming that drug distribution is uniform. Careful...
4.
LoRusso P, Krishnamurthi S, Rinehart J, Nabell L, Malburg L, Chapman P, et al.
Clin Cancer Res
. 2010 Mar;
16(6):1924-37.
PMID: 20215549
Purpose: To determine tolerability, pharmacokinetics, and pharmacodynamics of PD-0325901, a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor in advanced cancer patients. Experimental Design: Sixty-six...
5.
Arnold S, Rinehart J, Tsakalozou E, Eckardt J, Fields S, Shelton B, et al.
Clin Cancer Res
. 2010 Jan;
16(2):673-80.
PMID: 20068096
Purpose: 7-t-Butyldimethylsilyl-10-hydroxycamptothecin (AR-67) is a novel third generation camptothecin selected for development based on the blood stability of its pharmacologically active lactone form and its high potency in preclinical models....
6.
Lu X, Howard M, Talbert D, Rinehart J, Potter P, Jay M, et al.
AAPS J
. 2009 Feb;
11(1):120-2.
PMID: 19225893
No abstract available.
7.
Lu X, Howard M, Mazik M, Eldridge J, Rinehart J, Jay M, et al.
AAPS J
. 2008 May;
10(1):133-40.
PMID: 18446513
The pre-administration of dexamethasone (DEX) has previously been shown to enhance the anti-tumor efficacy of chemotherapeutic agents. The delivery of anti-inflammatory agents specifically to tumors via nanoparticle carriers is expected...
8.
Wang H, Wang Y, Rayburn E, Hill D, Rinehart J, Zhang R
Int J Oncol
. 2007 Mar;
30(4):947-53.
PMID: 17332934
Dexamethasone (DEX) is mainly used as an anti-emetic agent in cancer therapy. We have recently demonstrated that DEX pretreatment increases the antitumor activity of the cancer chemotherapeutic agents carboplatin and...
9.
Triozzi P, Bolger G, Neidhart J, Rinehart J, Saleh M, Allen K, et al.
Prostate
. 2005 Jul;
65(4):316-21.
PMID: 16015596
Background: Gonadotropin releasing hormone (GnRH)-DT vaccine elicits antibody that may inhibit prostate cancers indirectly by blocking GnRH induced gonadotropin release, and consequent androgen synthesis, and directly by immune effector and...
10.
Wang H, Li M, Rinehart J, Zhang R
Clin Cancer Res
. 2004 Mar;
10(5):1633-44.
PMID: 15014014
Purpose: The present study was undertaken to determine the effects of dexamethasone (DEX) pretreatment on antitumor activity and pharmacokinetics of the cancer chemotherapeutic agents carboplatin and gemcitabine. Experimental Design: Antitumor...